A new medicine to quickly reverse methamphetamine overdose
Official title: Clinical Development of a Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication
Funded at Clear Scientific, LLC · NIH-11178308 · Data updated 2026-11-12
This project aims to develop a fast-acting medicine called CS-1103 to help people experiencing severe methamphetamine intoxication.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clear Scientific, LLC NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | August 15, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $3,799,875 |
| NIH project number | 5U01DA058548-03 |
| Project ID | NIH-11178308 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals experiencing acute methamphetamine intoxication who require rapid reversal of its toxic effects.
✕Less likely to help
Patients not experiencing acute methamphetamine intoxication would not receive direct benefit from this specific treatment.
What this research studies
Methamphetamine intoxication is a growing health concern with no specific treatments currently available. This project focuses on developing CS-1103, a special molecule designed to quickly bind to methamphetamine in the blood. By binding to the drug, CS-1103 helps the body remove methamphetamine more rapidly through urine, effectively reversing its toxic effects. The goal is to gain FDA approval for CS-1103 to provide a much-needed antidote for acute methamphetamine intoxication. The team is currently completing early human trials and planning for the next phase.
Why it matters
Potential benefit: If successful, this medicine could provide a life-saving treatment for individuals experiencing severe and potentially fatal methamphetamine intoxication.
How similar studies have gone: While no current therapeutics are available for meth intoxication, CS-1103 has shown promising results in animal models, and this approach represents a novel strategy for drug reversal.
Where this research is happening
-
Clear Scientific, LLC
Cambridge, United States Active
Researchers
- Principal investigator: Li, Xinhua — Clear Scientific, LLC
- Study coordinator: Li, Xinhua
Related research
Other NIH-funded projects on the same topics.
-
A rapid antidote for methamphetamine intoxication that can be given by IV
A phase 2a study tests CS-1103, a fast-acting treatment designed to reverse methamphetamine intoxication and help clear the drug from the body.
-
New antidote for overdoses involving fentanyl and xylazine
A new injectable medicine that quickly removes both fentanyl and xylazine to reverse sedation and breathing problems in people overdosing on these drugs.
-
A new treatment to quickly remove synthetic opioids from the body
This study is testing a new treatment called CS-1103 that helps quickly remove dangerous synthetic opioids like fentanyl from the body, aiming to provide a single dose that can restore normal breathing and keep people safe after an overdose.
-
Developing a new antidote for fentanyl and xylazine overdoses
This study is working on a new treatment to help people who have overdosed on a mix of fentanyl and xylazine, which regular naloxone can't fix, so that they can breathe better and feel more alert again.
-
Developing a fast-acting antidote for methamphetamine overdose
This study is testing a new treatment called CS-1103 that helps quickly remove methamphetamine from the body, making it safer for people who have overdosed on the drug, and it's aimed at helping emergency departments handle these situations better.
-
New treatment to reverse opioid overdose
This study is testing a new injection called CS-1103 that aims to quickly reverse the effects of fentanyl overdoses, offering a potentially better option than the usual treatment, naloxone, for people who might need help in an emergency.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.